Does Repeated Dosing of Intravenous Ferric Carboxymaltose Alleviate Symptoms of Restless Legs Syndrome?

被引:2
|
作者
Park, Hea Ree [1 ]
Choi, Su Jung [2 ]
Joo, Eun Yeon [3 ]
机构
[1] Inje Univ, Ilsan Paik Hosp, Dept Neurol, Coll Med, Goyang 10380, South Korea
[2] Sungkyunkwan Univ, Grad Sch Clin Nursing Sci, Seoul 04514, South Korea
[3] Sungkyunkwan Univ, Neurosci Ctr, Samsung Med Ctr, Sch Med,Dept Neurol, Seoul 16419, South Korea
基金
新加坡国家研究基金会;
关键词
RLS; ferric carboxymaltose; iron; intravenous; IRON-DEFICIENCY; CLINICAL-EFFICACY; EKBOM DISEASE; PLACEBO; SUCROSE;
D O I
10.3390/jcm11061673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Several studies have reported the efficacy of intravenous (IV) iron for patients with restless legs syndrome (RLS), but little is known about the efficacy or safety of repeated IV iron treatment. The aim of this study was to evaluate the effectiveness of repeated doses of IV ferric carboxymaltose (FCM) in treating RLS symptoms. Methods: Patients who received FCM more than twice for RLS from April 2016 to January 2020 were retrospectively reviewed. Patients who had shown positive response to initial IV FCM re-visited the clinic when their symptoms returned, and received repeated IV FCM (1000 mg). Blood iron panels were measured before initial and repeated IV FCM. We defined 'responders' as patients with a greater than 40% decrease in International Restless Legs Study Group Severity Scale (IRLS) compared with pre-treatment levels. Results: A total of 42 patients, including 26 with primary RLS, 5 with gastrectomy, and 11 with anemia, completed the evaluation. Patients received IV FCM infusion 2-4 times. A total of 21 of 26 (80.8%) primary cases of RLS, 4 of 5 (80.0%) patients with a history of gastrectomy, and 9 of 11 (81.8%) patients with anemia responded to repeated FCM treatment. Serum ferritin levels of patients with primary RLS were higher before the second treatment than the baseline levels. There were no serious adverse events observed in the study. Conclusions: Repeated IV FCM for recurring symptoms is an effective treatment for primary RLS and RLS associated with iron deficiency. Serum ferritin might not be a reliable factor to monitor the sustained effects of IV iron for RLS.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome
    Park, Hea Ree
    Choi, Su Jung
    Joo, Eun Yeon
    Allen, Richard P.
    SLEEP MEDICINE, 2020, 75 : 81 - 87
  • [2] Ferric Carboxymaltose in Patients With Restless Legs Syndrome and Nonanemic Iron Deficiency: A Randomized Trial
    Trenkwalder, Claudia
    Winkelmann, Juliane
    Oertel, Wolfgang
    Virgin, Garth
    Roubert, Bernard
    Mezzacasa, Anna
    MOVEMENT DISORDERS, 2017, 32 (10) : 1478 - 1482
  • [3] Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome
    Cho, Yong Won
    Allen, Richard P.
    Earley, Christopher J.
    SLEEP MEDICINE, 2016, 25 : 16 - 23
  • [4] Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder
    DelRosso, Lourdes M.
    Ferri, Raffaele
    Chen, Maida L.
    Kapoor, Vidhi
    Allen, Richard P.
    Mogavero, Maria Paola
    Picchietti, Daniel L.
    SLEEP MEDICINE, 2021, 87 : 114 - 118
  • [5] Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis
    Khan, Ayesha
    Kumar, Harsh
    Rai, Kuldeep Dalpat
    Saeed, Anzel
    Ishtiaq, Jawad
    Alam, Muhammad Tanveer
    Chawla, Sakshi
    Haque, Md Ariful
    FRONTIERS IN NEUROLOGY, 2025, 15
  • [6] Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome
    Schneider, Juliane
    Krafft, Alexander
    Manconi, Mauro
    Huebner, Astrid
    Baumann, Christian
    Werth, Esther
    Gyr, Thomas
    Bassetti, Claudio
    SLEEP MEDICINE, 2015, 16 (11) : 1342 - 1347
  • [7] Clinical efficacy and safety of IV ferric carboxymaltose in restless legs syndrome: A meta-analysis of 537 patients
    Qadri, Syeda Nimra
    Jamil, Saifullah
    Zahid, Subhan
    Asghar, Tehreem
    Gillani, Syeda Muzna
    Qasim, Soban Ali
    Kambar, Tilyan
    Ul Abideen, Zain
    Brohi, Usama
    Tareen, Sammon Khan
    Tareen, Palay Khan
    Kumari, Sandhya
    Kumar, Satesh
    Khatri, Mahima
    SLEEP MEDICINE, 2024, 124 : 244 - 253
  • [8] Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial
    Earley, Christopher J.
    Garcia-Borreguero, Diego
    Falone, Mark
    Winkelman, John W.
    SLEEP, 2024, 47 (07)
  • [9] Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome
    Cho, Yong Won
    Allen, Richard P.
    Earley, Christopher J.
    SLEEP MEDICINE, 2018, 42 : 7 - 12
  • [10] Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder
    DelRosso, Lourdes M.
    Reuter-Yuill, Lilith M.
    Cho, Yeilim
    Ferri, Raffaele
    Mogavero, Maria P.
    Picchietti, Daniel L.
    SLEEP MEDICINE, 2022, 100 : 488 - 493